Pharma & Biotech Most Active Sector in UK M&As
The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up.
The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up.
However M&A activity targeting the United Kingdom - standing at £37.5bn in H1 2014 - represented the lowest half-year value since H1 2010 (£37 bn) and a 12.5% drop from H1 2013 (£42.9bn).
The Novartis acquisition was the only mega-deal in the region so far, and the lack of large transactions pulled the UK M&A value down in Q1. However, the second quarter witnessed a stark improvement (up 156.5% from Q1, from £10.5bn to £27bn) and represented the highest quarterly value in the country since Q2 2012. Needless to say, the proportion of PMB M&A in the UK and globally would have been considerably larger if the £69bn proposed acquisition of AstraZeneca by Pfizer had gone through.
http://www.mergermarket.com/pdf/MergermarketTrendReport.H12014.UK.pdf
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Merck, Lilly Commit Large Investments to US R&D and Manufacturing Expansion
May 12th 2025Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing $250 million to pharmaceutical innovation and workforce development through its extended partnership with Purdue University.
